CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Jan. 01, 2022	Dec. 26, 2020
Cash Flows from Operating Activities:
Net income	$ 33,634	$ 90,510
Non-cash items:
Depreciation and amortization	72,934	62,377
Impairment of assets	5,144	1,028
Share-based compensation expense	19,262	18,406
Amortization of deferred finance costs	2,608	425
(Benefit) provision for losses on inventory	(280)	3,779
Gain on closing of transaction	9,603	32,613
Deferred tax benefit	1,999	(3,953)
Contingent consideration expense	10,272	0
Other non-cash operating activities	1,103	89
Amortization of fair value inventory step-up	5,295	0
Change in operating assets and liabilities:
Change in accounts receivable	(28,736)	18,588
Change in inventories	11,589	(33,728)
Change in prepaid income taxes	4,400	1,181
Change in other assets and other liabilities	(6,010)	2,687
Change in accounts payable and accrued expenses	(19,398)	(21,518)
Net cash provided by operating activities	104,213	107,258
Cash Flows from Investing Activities:
Capital expenditures	(61,394)	(25,408)
Acquisition	(2,500)	(16,606)
Proceeds from divestitures	10,642	44,587
Proceeds from sale of property, plant and equipment	1,419	1,085
Net cash (used in) provided by investing activities	(51,833)	3,658
Cash Flows from Financing Activities:
Net (decrease) in short-term loans	0	(60,000)
Repayment of term loan borrowings	(13,125)	(13,125)
Proceeds from employee stock purchase plan	4,210	4,012
Proceeds from exercise of stock options	1,923	3,838
Other	8	(32)
Net cash used in financing activities	(6,984)	(65,307)
Effect of exchange rates on cash and cash equivalents	(824)	6,082
Net Change in Cash and Cash Equivalents	44,572	51,691
Cash and Cash Equivalents at Beginning of Period	192,305	137,311
Cash and Cash Equivalents at End of Period	236,877	189,002
Supplemental Disclosures of Cash Flow Information:
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 25,385	$ 5,878